Dataset from A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009401
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and tolerability of the study drug
(DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to
receive DX-2930 or placebo.
创建时间：
2024-11-26
